Intravenous Administration News
-
Showcase
Zeneo® Adrenaline: A New Innovative Formulation
Anaphylactic shock is an absolute medical emergency. When anaphylactic shock is suspected, emergency services must be called and emergency first aid administered immediately. The only first-line treatment for anaphylactic shock is injectable adrenaline1. In the USA: 1.6% to 5.1% of the population has experienced anaphylactic shock, 1% of hospitalizations are caused by it, 0.1% of patients ...
By Crossject
-
Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The agency warns Klebsiella bacteria have increasingly developed antimicrobial resistance, most recently to the ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
Bayer driving innovation in radiology with new research across the portfolio presented at ECR
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
By Bayer AG
-
Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher and Suono Bio are the winners of Bristol-Myers Squibb’s Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech ...
By Suono Bio
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
-
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” ...
-
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
By xCures
-
Synbiotic Health Announces the Expansion of their R&D and Commercial Capabilities with the Acquisition of a New Facility in Madison, Wisconsin
Synbiotic Health, a market leader in the discovery, development, and commercialization of probiotic ingredients, announced that the company has expanded its R&D and commercial capabilities with the acquisition of a 43,000 sf facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialization of advanced probiotic ingredients for improved health. The Madison ...
-
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeValent
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s ...
-
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
-
Treatment of Prostatitis - What Forms of Medicines Released?
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
-
Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 Jeffries Innovation inMental Health Summit. Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are ...
-
Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. The ...
-
Transformative Dementia and Alzheimer’s treatment company Kurve Therapeutics launches $50m equity crowdfunding raise
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise. Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the ...
-
Possible Side Effects of Local Anesthesia
Small procedures on the body, like a skin biopsy, are great candidates for local anesthesia. An injection or topical cream may be used. If you’ve ever had an injection by a dentist, you’ve had a local anesthetic. Fast-acting, virtually pain-free and convenient, local anesthetics enable much of medicine to occur. Patients can remain awake and leave following their procedure. After ...
-
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX treatment courses valued at ...
-
Kurve Therapeutics, Innovative Medtech and Specialty-Drug Company Focused on Treating Neurodegenerative Diseases, Files Regulation A Offering
Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 ...
-
Linear Health Sciences’ Early Success Highlighted at SEMDA Medical Device Conference
ATLANTA, Georgia – The early success of Linear Health Sciences in developing its Orchid™ Safety Release Valve to prevent unwanted dislodgement of IV catheters was highlighted in a panel discussion at the recent annual conference of the Southeastern Medical Device Association (SEMDA). Dan Clark, co-founder and Chief Marketing Officer of Linear Health Sciences, represented the company ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you